Trending in Pharma - Pharma on Medika Life

Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.

Ivermectin is NOT Hydroxychloroquine. Why is the FDA Ignoring a Potential Covid Treatment?

Robert Turner, Founding Editor - January 10, 2021

Ivermectin has shown promise as a potential treatment. It needs to be urgently evaluated under the guidance of the FDA

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

Of Measles and Midterms

BIO – Biotech Without Borders

New Alzheimer’s Drugs Will Worsen Inequality

Does Pharma Need Independent DNA Oversight?

LATEST

TRENDING

The Evolution of Quinine to Hydroxychloroquine, Covid’s Snake Oil

Ivermectin is NOT Hydroxychloroquine. Why is the FDA Ignoring a Potential Covid Treatment?

How to Wee Away your UTI. New Research from Rutgers

Covid Patients in India Warned About Scammers Selling Fake Medicines and Cures

FINN Partners Brings Aboard the Pharmacy Podcast Network

Up, Up, And Away: The Evolution of Speed

A Mother’s Fight for Life and a Few More Weeks With Her Sons #tofersen4lisa

Todd Eury, Pharmacy Podcast Network

Advocating for Leaders in Pharmacy. Drawing Attention to Unsung Heroes

Aspirin. Your Heart’s Best Friend, or Maybe Not

EDITORS CHOICE

Of Measles and Midterms

Does Pharma Need Independent DNA Oversight?

Lilly commits Insulin Value Program, With $35 Copay Card

Ivermectin is NOT Hydroxychloroquine. Why is the FDA Ignoring a Potential Covid Treatment?

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories